Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Allison

Showing results (51-60 of 226) with videos related to

Pageof 23
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 22, 2010
Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenanceVirginia A Pedicord, Welby Montalvo, Ingrid M Leiner, et al.
Immunobiology|March 31, 2012
Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe"Michael A Curran, Margaret K Callahan, Sumit K Subudhi, et al.
Current Opinion in Immunology|February 9, 2006
Principles and use of anti-CTLA4 antibody in human cancer immunotherapyKarl S Peggs, Sergio A Quezada, Alan J Korman, et al.
The Journal of Clinical Investigation|June 17, 2006
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cellsSergio A Quezada, Karl S Peggs, Michael A Curran, et al.
Cancer Immunology Research|July 20, 2014
Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motilityTsvetelina Pentcheva-Hoang, Tyler R Simpson, Welby Montalvo-Ortiz, et al.
Immunological Reviews|April 15, 2011
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradicationSergio A Quezada, Karl S Peggs, Tyler R Simpson, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2002
Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c miceArthur A Hurwitz, Timothy J Sullivan, Raymond A Sobel, et al.
Plos One|May 12, 2011
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine productionMichael A Curran, Myoungjoo Kim, Welby Montalvo, et al.
The Journal of Experimental Medicine|April 2, 2014
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapyXiaozhou Fan, Sergio A Quezada, Manuel A Sepulveda, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2003
B7x: a widely expressed B7 family member that inhibits T cell activationXingxing Zang, P'ng Loke, Jayon Kim, et al.
Pageof 23

Showing results (51-60 of 226) with videos related to

Sort By:
Pageof 23
Proceedings of the National Academy of Sciences of the United States of America|December 22, 2010
Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenanceVirginia A Pedicord, Welby Montalvo, Ingrid M Leiner, et al.
Immunobiology|March 31, 2012
Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe"Michael A Curran, Margaret K Callahan, Sumit K Subudhi, et al.
Current Opinion in Immunology|February 9, 2006
Principles and use of anti-CTLA4 antibody in human cancer immunotherapyKarl S Peggs, Sergio A Quezada, Alan J Korman, et al.
The Journal of Clinical Investigation|June 17, 2006
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cellsSergio A Quezada, Karl S Peggs, Michael A Curran, et al.
Cancer Immunology Research|July 20, 2014
Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motilityTsvetelina Pentcheva-Hoang, Tyler R Simpson, Welby Montalvo-Ortiz, et al.
Immunological Reviews|April 15, 2011
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradicationSergio A Quezada, Karl S Peggs, Tyler R Simpson, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2002
Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c miceArthur A Hurwitz, Timothy J Sullivan, Raymond A Sobel, et al.
Plos One|May 12, 2011
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine productionMichael A Curran, Myoungjoo Kim, Welby Montalvo, et al.
The Journal of Experimental Medicine|April 2, 2014
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapyXiaozhou Fan, Sergio A Quezada, Manuel A Sepulveda, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2003
B7x: a widely expressed B7 family member that inhibits T cell activationXingxing Zang, P'ng Loke, Jayon Kim, et al.
Pageof 23